journal article·2022-09-02

Quality by design approach for formulation development and evaluation of carboplatin loaded ethylcellulose nanosponges

Muhammad Ahsan Hafiz, Nasir Abbas, Nadeem Irfan Bukhari

Publisher page

Abstract

Nanosponges, porous nanocarriers were explored for encapsulation of carboplatin by employing a quality by design approach. Nanosponges were prepared by double emulsion solvent evaporation using the central composite design. Ethylcellulose, 450 mg, polyvinyl alcohol, 2.3% (w/v) and phase evaporation rate, 760 rpm yielded the optimized spherical particles of size 272.92 ± 12.31 nm, PDI 0.390, with zeta charge of −22.3 mV. The entrapment efficiency of carboplatin-loaded nanosponges was 56.27 ± 2.52%. A sustained carboplatin release of 79.03% and 95.94% within 12 h at pH 4.5 and 6.8, respectively suggested that nanosponges could be promising carriers for sustained release of hydrophilic therapeutic candidates.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Punjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan

References (41)

Show source-provided references
1. 10.1016/j.colsurfb.2016.02.02610.1016/j.colsurfb.2016.02.026 ↗
2. 10.1208/s12249-014-0139-210.1208/s12249-014-0139-2 ↗
3. 10.1208/s12248-012-9339-410.1208/s12248-012-9339-4 ↗
4. 10.1080/10717544.2016.120515810.1080/10717544.2016.1205158 ↗
5. 10.3109/03639045.2012.69461010.3109/03639045.2012.694610 ↗
6. Abdul A. H. · IJPSN · 2019 · 13 · 476610.37285/ijpsn.2020.13.1.5 ↗
7. Bolmal U. B. · PCI-Approved-IJPSN. · 2013 · 6 · 193410.37285/ijpsn.2013.6.1.3 ↗
8. 10.1016/j.jddst.2019.10130210.1016/j.jddst.2019.101302 ↗
9. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: quality risk management Q9. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-3.pdf
10. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: pharmaceutical development Q8(R2). https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
11. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: pharmaceutical quality systems (Q10). https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human_en.pdf
12. 10.1080/17425247.2018.150476810.1080/17425247.2018.1504768 ↗
13. 10.1208/s12249-015-0465-z10.1208/s12249-015-0465-z ↗
14. El-Habashy S. E. · Int. J. Nanomedicine. · 2016 · 11 · 2369
15. 10.2478/v10007-011-0022-610.2478/v10007-011-0022-6 ↗
16. 10.3109/10717544.2014.91676810.3109/10717544.2014.916768 ↗
17. 10.1208/s12249-009-9220-710.1208/s12249-009-9220-7 ↗
18. 10.3109/1083745100373928910.3109/10837451003739289 ↗
19. 10.18433/J3K30810.18433/J3K308 ↗
20. 10.1016/j.ijpharm.2015.10.05710.1016/j.ijpharm.2015.10.057 ↗
21. Aldawsari H. M. · Int. J. Nanomedicine. · 2015 · 10 · 89310.2217/nnm.14.236 ↗
22. 10.1016/j.ejps.2016.09.03810.1016/j.ejps.2016.09.038 ↗
23. 10.1016/B978-0-12-815799-2.00014-910.1016/B978-0-12-815799-2.00014-9 ↗
24. Lan Z. · J. Pharm. Sci. · 2017 · 12 · 1
25. 10.1208/s12248-013-9472-810.1208/s12248-013-9472-8 ↗
26. Nayak, A. K.; Ahmed, S. A.; Beg, S.; Tabish, M.; Hasnain, M. S. Application of Quality by Design for the Development of Biopharmaceuticals. In: Pharmaceutical quality by design. Academic Press: London, 2019; pp. 399–411. DOI: 10.1016/B978-0-12-815799-2.00019-8.10.1016/B978-0-12-815799-2.00019-8 ↗
27. 10.3109/978142007423910.3109/9781420074239 ↗
28. 10.3109/10717544.2014.94864310.3109/10717544.2014.948643 ↗
29. 10.1208/s12248-010-9185-110.1208/s12248-010-9185-1 ↗
30. 10.3390/polym1212290310.3390/polym12122903 ↗
31. 10.3109/03639045.2012.68105410.3109/03639045.2012.681054 ↗
32. 10.3109/03639045.2010.48726310.3109/03639045.2010.487263 ↗
33. 10.1023/B:PHAM.0000036917.75634.be10.1023/B:PHAM.0000036917.75634.be ↗
34. 10.1016/j.colsurfb.2003.10.00310.1016/j.colsurfb.2003.10.003 ↗
35. 10.1016/j.ajps.2015.09.00410.1016/j.ajps.2015.09.004 ↗
36. Tiwari A. · Am. J. Pharm. Tech. Res. · 2016 · 6 · 79
37. Pandav S. · J. Pharm. · 2014 · 2014 · 1
38. 10.1002/jps.260052121010.1002/jps.2600521210 ↗
39. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
40. 10.1039/C7RA06829H10.1039/C7RA06829H ↗
41. 10.2147/DDDT.S24050610.2147/DDDT.S240506 ↗